The study examined B cells as a possible treatment target in rheumatic heart disease (RHD). A 750-mRNA panel on rheumatic mitral valve tissue showed upregulated B-cell pathways, including CD20-associated and immunoglobulin genes. Children with RHD in Dakar, Senegal, then received rituximab in a feasibility study, and treatment was well tolerated. In a first-year safety analysis of the later randomised trial, treated children had falling anti-streptolysin O titres. They also showed clinical improvement compared with controls. The abstract gives no participant numbers or effect sizes, and the trial findings are preliminary.
Why it is interesting: No current therapy targets the autoimmune process behind rheumatic heart disease. This study links valve tissue findings to an early trial of B-cell depletion in children in Senegal.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.